Abbott’s Architect hepatitis B surface antigen (HBsAg) diagnostic test has been awarded the CE mark.

The HBsAg quantitative assay helps in the detection of acute and chronic Hepatitis B virus infections, and screens blood and blood products using the Architect immunochemistry system.

The test is a chemiluminescent microparticle immunoassay that enables clinicians to identify patients with low levels of HBsAg.

Biomnis biologist Thoai Duong Ly said that the Architect test helps to identify mutant strains of the Hepatitis B virus.